Cognition Therapeutics wins US patent for new crystalline form of zervimesine through 2045

• Cognition Therapeutics won a U.S. patent covering a new crystalline form of its lead candidate zervimesine (CT1812).
• The composition-of-matter protection runs through 2045, with potential FDA-related extension of up to five years.
• Claims also cover a manufacturing process plus treatment methods for Alzheimer’s disease, dry AMD, dementia with Lewy bodies.
• Management plans an FDA meeting next week on registrational endpoints in dementia with Lewy bodies.
• Manufacturing of the newly patented form is slated to start in Q1 2027 for a registrational trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130600PRIMZONEFULLFEED9844309) on October 13, 2026, and is solely responsible for the information contained therein.